ABVC Stock Performance, Insider Transaction and News

ABVC - ABVC Biopharma, Inc.

Market Cap	9.99M	P/E	-	EPS this Y	-	Ern Qtrly Grth	-
Income	-11.37M	Forward P/E	-6.86	EPS next Y	-	50D Avg Chg	-42.00%
Sales	136.4k	PEG	-	EPS past 5Y	-	200D Avg Chg	-55.00%
Dividend	N/A	Price/Book	5.93	EPS next 5Y	-	52W High Chg	-84.00%
Recommedations	3.00	Quick Ratio	0.03	Shares Outstanding	12.42M	52W Low Chg	26.00%
Insider Own	22.93%	ROA	-44.55%	Shares Float	9.14M	Beta	0.81
Inst Own	2.95%	ROE	-320.36%	Shares Shorted/Prior	111.15K/127.15K	Price	3.02
Gross Margin	-24.11%	Profit Margin	-	Avg. Volume	767,356	Target Price	-
Oper. Margin	-833.72%	Earnings Date	Nov 13	Volume	423,408	Change	-16.34%

Healthcare | Biotechnology | United States

About ABVC Biopharma, Inc.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

ABVC Biopharma, Inc. News

11/14/24	ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones
10/22/24	ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
08/15/24	ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
07/09/24	ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI
07/02/24	ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
06/25/24	ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market
06/12/24	ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue
05/24/24	Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M
05/22/24	ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M
05/15/24	Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M
05/09/24	Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
04/18/24	AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
08:00 AM	ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
04/10/24	ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
03/26/24	ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
03/21/24	AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
03/19/24	ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
03/14/24	ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
02/27/24	ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
02/15/24	ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

ABVC Chatroom

specctham Posted - 1 day ago

$ABVC What a gift this is. Holy sh.. 🤫

cam109 Posted - 3 days ago

$ABVC all this really needs is volume to go. Great resistance at 52 week low. 90% positive earnings report. Just bought in $15k.

MrAlientrader Posted - 3 days ago

$ABVC all positive, i do not see any negative from the ER

STOCKSGambino Posted - 3 days ago

$ABVC https://x.com/StocksGambino/status/1857061770688344459

Scanners_Free Posted - 3 days ago

$ABVC ER OUT

Pathonix Posted - 4 days ago

$ABVC hawking vitamins as drugs enough said

specctham Posted - 1 week ago

$ABVC Looks like the phase trials coming out bad !

Pathonix Posted - 1 week ago

$ABVC best way to loose 100 percent of your money invest in a company with fluff PR's that uses shares not money. A company that hawks vitamins as real drugs... Lol

gpoop4422 Posted - 1 week ago

$ABVC this thing is the worst.

specctham Posted - 1 week ago

$ABVC wtf

Pathonix Posted - 1 week ago

$ABVC hyped PR's vitamins touted as drugs - lol

Rachel20201 Posted - 1 week ago

$ABVC

StocksSchmocks Posted - 10/30/24

$ABVC adding swing play .70

SRinvestment Posted - 10/29/24

$ABVC adding some more in this dip

STOCKSGambino Posted - 10/29/24

$ABVC ,,

STOCKSGambino Posted - 10/29/24

$ABVC

STOCKSGambino Posted - 10/29/24

$ABVC ''phase 2 study expected to be completed 2h 2024'' ''phase 2b trial expected to be completed by end of Q4-2024'' ''fda meeting in 2024''

STOCKSGambino Posted - 10/29/24

$ABVC ''EPS up 86.8% in Q2 2024 from Q2 2023'' ''Psychiatric drug with AiBtl BioPharma, inc:potential income Up to $667 million. potential milestone payment from AiBtl BioPharma: $7 million in cash'' ''Vitargus Licensing with ForSeecon Eye Corporation: potential income: Up to $187 million'' ''Oncology products Licensing with OncoX BioPharma, Inc: potential income: up to $105 million''

specctham Posted - 10/28/24

$ABVC Still 10M float. Should go to 3-4

nav1234678 Posted - 10/28/24

$ABVC going to get a move like $HCTI

BobAxe Posted - 10/28/24

$ABVC moving

STOCKSGambino Posted - 10/28/24

$ABVC

STOCKSGambino Posted - 10/28/24

$ABVC so much going on with this company only amatter of time for her to run like MNPR EVOK etc

SRinvestment Posted - 10/28/24

$ABVC adding some for a swing

Pathonix Posted - 10/28/24

$ABVC Always know this is a completely hype producing and hawking vitamins as drugs thing. No real money it's always inflated phantom share deals with other subsidies or other such crock of bull

WealthExchange Posted - 10/25/24

$ASTI we took the swing yesterday from 2.6, currently 2.9. Believe this could be a gapper next week. $ABVC Been loading in the .50s. We trimmed some on the pop but holding a majority. Expecting significant news here + very strong PA so far. Both are 50-100% candidates for next week

RETAlerts Posted - 10/25/24

$ABVC at 0.74 is starting to show some signs of a further gap up, 10% up since landing on our scanner, stay tuned for more price updates. (15 minute delay)

BobAxe Posted - 10/25/24

$ABVC red to green and moving

STOCKSGambino Posted - 10/25/24

$ABVC added the dip + SSR is on

StockScanners Posted - 10/24/24

$ABVC Keep watch if this holds above .66